Tag: Food and Drug Administration (FDA) ⋅ Page 2

Professor Lietzan Quoted in Article about CBD

Professor Erika Lietzan was quoted recently in a Philadelphia Inquirer story, “Selling CBD in food is illegal, FDA says. So why are so many retailers selling it?,” about the sale of foods and dietary supplements containing CBD, or cannabidiol, which is derived from cannabis. CBD is reputed to have health benefits, and after FDA approved a new drug containing CBD in…

Professor Lietzan Quoted by CBS News on Pharmaceutical Manufacturing Recall

Professor Erika Lietzan was recently quoted by CBS News in a Moneywatch article relating to pharmaceutical manufacturing, “Drugmaker behind ibuprofen recall has history of FDA violations.” Last month New Jersey drugmaker Tris Pharma doubled its recall of infant ibuprofen, and CBS News spoke with Professor Lietzan about the company’s manufacturing history.  She described some of the “red flags” in a…

Professor Lietzan Presents at Symposium on Federal Regulation of Cannabis

Professor Erika Lietzan presented her most recently completed article at a symposium on federal regulation of cannabis. The symposium, hosted by the Food and Drug Law Institute, convened academics, scientists from the Food and Drug Administration, lawyers from private practice, and industry developing cannabis-based products, to consider the path forward for a federal regulatory regime. Professor Lietzan’s forthcoming article in the American…

Professor Lietzan Receives ‘Best Lawyer’ honors

Professor Erika Lietzan has been named a “Best Lawyer in America”  in FDA Law and in Biotechnology and Life Sciences Law.  This marks the sixth year in a row for FDA law and the twelfth year in a row for biotechnology law.  The Best Lawyers honor is meant to identify the top 5 percent of practicing attorneys in the United…

Professor Lietzan Speaks at Food & Drug Law Institute’s Annual Conference

On May 4, Professor Erika Lietzan participated in the perennially popular closing session – on significant litigation in 2017 and cases to watch in 2018 – of the Food & Drug Law Institute’s annual conference.  FDLI is the primary professional association for specialists in food and drug law.  The annual meeting brought together more than 900 law professors, practicing lawyers,…

Professor Lietzan Featured on Webcast about New Uses for Established Drugs

On March 29, Professor Erika Lietzan was the featured speaker in a webcast from the Syracuse College of Law’s IP Tech Law Center.  She spoke with Shubha Ghosh about ensuring effective patent and regulatory exclusivity incentives for the development of new uses for already established drugs.  Her recent article on this topic, “Paper Promises for Drug Innovation” will be published…

Professor Lietzan Speaks About FDA Regulation of Direct-to-Consumer Genetic Testing

Professor Erika Lietzan spoke on March 16 at “Frontiers in Precision Medicine III: Will Personalized Medicine Improve Population Health?” –  a full day symposium hosted by the University of Utah S.J. Quinney School of Law, the Huntsman Cancer Institute at the University of Utah, and the School of Medicine at the University of Utah.  Professor Lietzan’s presentation focused on FDA…

Professor Lietzan Speaks at Conference about New Uses of Established Drugs

On February 8, Professor Erika Lietzan spoke at the conference, “Clinical Innovation: Fair and Effective Incentives for New Uses of Established Drugs,” convened in Washington, DC, by University College London (UCL) and the Georgetown University Law Center (GULC). This invitation-only conference gathered more than 40 experienced thought leaders — including scientists, industry executives, lawyers, law professors, business professors, judges, retired judges, and regulators, most with several decades of…

Professor Lietzan Speaks on Panel at Supreme Court IP Review

Professor Erika Lietzan recently served as a panelist at the Supreme Court IP Review held at the Chicago-Kent College of Law. She discussed Sandoz, Inc. v. Amgen. Inc., a case decided by the Supreme Court last June. In October 2014, Amgen, a biopharmaceutical company which manufactures Neupogen, an innovative bone marrow stimulant, sued Sandoz, a biopharmaceutical company which manufactures Zarxio,…